10 Stocks on Jim Cramer’s Radar

2. Eli Lilly and Company (NYSE:LLY)

Number of Hedge Fund Holders In Q2 2025: 119

Eli Lilly and Company (NYSE:LLY) continues to be one of Cramer’s top pharmaceutical stocks. He has consistently discussed the firm in 2025 and praised it on several fronts. These include Eli Lilly and Company (NYSE:LLY)’s weight loss drugs, the firm’s plans to establish a robust manufacturing process in America, and new drugs in its pipeline. However, more recently, Cramer has admitted that the firm needs some catalysts for the shares to make further gains. Here is what he said about Eli Lilly and Company (NYSE:LLY) in this appearance before interviewing the firm’s CEO, David Ricks:

“I’ve followed Dave Ricks for a long time. Shares of Eli Lilly are on the move. Company blew past the estimates for the third quarter and hiked guidance, which is very different from almost every other drug company other than [inaudible] and it’s because of the weight loss. If the market weren’t that bad the stock would probably be up forty or fifty.”